Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial
- Resource Type
- Article
- Source
- In
Journal of Cystic Fibrosis May 2023 22(3):464-470 - Subject
- Language
- ISSN
- 1569-1993